You are here

Article Text

Article menu
Download PDFPDF
Letter
Ceftriaxone drug alert: no longer for first line use in meningococcal sepsis
  1. S N Faust1,
  2. A J Pollard2,
  3. S Nadel3,
  4. N Ninis3,
  5. M Levin3
  1. 1
    Welcome Trust Clinical Research Faculty, University of Southampton, Southampton, UK
  2. 2
    Department of Paediatrics, University of Oxford, Oxford, UK
  3. 3
    Department of Paediatrics, Imperial College School of Medicine, St Mary’s Hospital, London, UK
  1. Saul N Faust, Wellcome Trust Clinical Research Facility, Mailpoint 218, Level C, West Wing, Southampton University Hospital, Tremona Road, Southampton SO16 6YD, UK; s.faust{at}soton.ac.uk

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Although UK and international high income country practice has been to recommend ceftriaxone or cefotaxime as first line therapy for the initial treatment of paediatric sepsis, the US FDA has issued an alert1 that has led to changes in the US label for ceftriaxone.2 Due to concerns regarding the potential for calcium chelation …

    View Full Text

    Footnotes

    • Competing interests: None declared.